This Month
Cancer therapy biotech Celleo in private fund-raising round
According to the pitch, while drugs for cancer have advanced significantly, the manufacturing is overly reliant on manual processes and creating bottlenecks.
Sonic Healthcare set to lift stake in Microba Life Sciences
The raising comes after Microba has lost 36 per cent of its sharemarket value in the past 12 months.
This meat just became legal in Australia (and we tried it first)
One local producer is ready to start filling restaurants and supermarket shelves with lab-grown meat, a product on the cutting edge of food technology. Would you eat it?
UNSW spin-off JumpStart Fertility lands US backer
JumpStart Fertility is seeking to boost embryo development and improve success rates by 60 per cent.
‘Next Cochlear’ launches ASX float to sell its ‘medical Lego’
Tetratherix, a medical device company backed by Xero founder Rod Drury, is set to make its ASX debut later this month with an ambitious global pitch for investors.
May
Labor takes $27m stake in breakthrough eye biotech
Melbourne biotech PolyActiva says it hopes to be the next Cochlear by selling its eye drug dispensing system to millions globally.
Tetratherix joins the small-cap run for the ASX with $115m IPO
The start-up founded by University of Sydney researchers is trying to commercialise a new regenerative treatment and being advised by Barrenjoey and Morgans.
Medtech EBR Systems upsizes raising to $56m after FDA approval
Fund managers were offered shares at $1 apiece, representing an 18 per cent discount to the last close.
Barrenjoey, Morgans test IPO appetite for $100m-plus Tetratherix
In the lead-up to the IPO, Tetratherix has tapped Emma Cleary – a former CFO of Navis Capital’s $1.5 billion Device Technologies – to chair its board.
The Aussie bringing Black Mirror-esque brain tech to reality
This neurologist has built technology allowing humans to control machines with just their thoughts. Now he’s racing Tesla’s founder to take it to the masses.
Biotech Dimerix lands $940m licensing deal for kidney drug sales
The Melbourne-based company says it has landed one of the biggest licensing deals in Australian biotech history.
Wentworth buys $200m asset for $1.5b BlackRock life sciences JV
The North Ryde deal comes after Wentworth in 2023 struck a deal with Sydney University to develop a $500 million life sciences hub.
April
Diagnostics company BlinkLab seeks funds ahead of FDA submission
Street Talk understands the ASX-listed company’s stockbrokers Alpine Capital and Westar Capital will launch a $5 million single-tranche placement on Tuesday morning.
This $1.3b biotech is still run out of a spare bedroom in Melbourne
It’s been a volatile few years for Neuren, the neurological disorder treatment group which has seen shares rocket, then slump. Now it has a promising new drug.
Cochlear-backed Epiminder targets 2025 IPO as FDA authorisation lands
E&P Capital, which helped Epiminder raise funds this year, will lead the bookbuild alongside Morgans.
How this $115b ASX giant plans to win from both sides of the trade war
On the front line of the tit-for-tat tariff fight between the US and China, Australian companies are trying to find a way to play both sides.
Pharmaceuticals to be hit by ‘major’ Trump tariff, CSL slumps 5pc
Investors are in panic as Australian drug companies could be the next victims in an expansion of the US trade war.
Teal corflute bandit could have been a medtech star
Peter Jordan’s timing at leaving dud businesses is better than his ability to get away from scenes of election poster shenanigans.
Phil King’s Regal writes Opthea to zero and backs off risky bets
The veteran stockpicker told investors the firm would review how its $220 million wager on the biotech went so wrong “to ensure it does not occur again”.
March
Opthea in active talks with funders after second trial fails
The little hope left for Opthea shareholders has been crushed after the biotech said a second late-stage trial of its eye disease treatment had failed.